Association of Henoch-Scho?nlein purpura and Graves' disease by 源��뜒�씗 et al.
3. Johnson RJ, Segal MS, Srinivas T et al. Essential hypertension,
progressive renal disease, and uric acid: a pathogenetic link?
J Am Soc Nephrol 2005; 16: 1909–1919
doi:10.1093/ndt/gfl261
Advance Access publication 31 July 2006
Association of Henoch–Scho¨nlein purpura
and Graves’ disease
Sir,
We read with interest the article ‘Henoch–Scho¨nlein purpura
associated with propylthiouracil overdose’ by Lee et al. [1].
They reported the first case of a patient with Graves’ disease
who developed Henoch–Scho¨nlein purpura (HSP) after a
propylthiouracil overdose. We wondered whether HSP
would have occurred if she had maintained the prescribed
dosage. Although a causal relationship between HSP and
Graves’ disease or propylthiouracil use is unclear, we recently
reported the case of a patient who developed Graves’ disease
during ciclosporin treatment for severe HSP nephritis [2],
and speculated that these two diseases might be related.
In the past 10 years, we have experienced two additional
cases of HSP associated with Graves’ disease.
Patient 1
A 28-year-old previously healthy woman presented with
a skin eruption starting at 12 weeks gestation. Physical
examination revealed palpable purpura of the lower extre-
mities extending to the knees, but otherwise was unremark-
able. Her past medical history revealed that she had been
diagnosed with Graves’ disease 4 years previously and had
been treated with propylthiouracil for 3 years. One year ago,
she came to maintain euthyroid state without propylthiour-
acil treatment. Family history revealed that her mother
and younger sister had hypothyroidism. Her blood pressure
was normal, and laboratory tests, including complete
blood count, BUN, creatinine, aminotransferases, alkaline
phosphatase, urinalysis, hepatitis B and C and human
immunodeficiency virus serologies, were negative or
normal. Erythrocyte sedimentation rate (ESR) was 59mm/h
and serum IgA level 429mg/dl (normal reference values<300).
About 1 month later, she experienced a cutaneous flare,
which persisted several weeks, without evidence of renal
disease or hypertension.
Patient 2
A 12-year-old girl was admitted to the hospital with a history
of fatigue, abdominal pain, vomiting and dark urine.
On admission, she had arthralgia, oedema and a palpable
purpuric rash on the lower extremities. Past medical history
revealed that a tonsillectomy had been performed at the age of
9 years, and Graves’ disease was diagnosed at the age
of 10 years. She was commenced on propylthiouracil and
subsequently remained euthyroid state on a stable dose
of propylthiouracil. She was hypertensive, and laboratory
investigations were: ESR 59mm/h, BUN 74mg/dl, serum
creatinine 4.8, serum albumin 3.2 g/dl, cholesterol 177mg/dl,
serum IgA 291mg/dl, creatinine clearance 13ml/min/1.73m2,
antinuclear antibody negative and anti-ds DNA antibody
negative. Urinalysis showed many RBCs/HPF and proteinuria
30mg/dl. She was diagnosed as having acute nephritic type of
HSP nephritis, and treated with methylprednisolone pulse
therapy followed by prednisolone, calcium-channel blocker
(Madipine) and propylthiouracil. She achieved complete
remission of HSP nephritis including resolution of haematuria
and proteinuria at 1.4 years of follow-up. About 3 years after
the development of HSP, the patient is still in complete
remission without recurrence of vasculitis.
Our cases suggest that HSP may develop in a patient with
Graves’ disease receiving the usual dose of propylthiouracil
or no treatment. Therefore, it is likely that not only
propylthiouracil use but also Graves’ disease itself may be
a triggering factor for the development of HSP in susceptible
individuals. However, a large prospective study may further
elucidate the clear relationship between HSP and Graves’
disease or propylthiouracil use.
Conflict of interest statement. None declared.
The Institute of Kidney disease
Department of Pediatrics
Yonsei University College of Medicine
Seoul
Korea
Email: jsyonse@yumc.yonsei.ac.kr
Jae Il Shin
Jee Min Park
Ji Hong Kim
Jae Seung Lee
Duk Hee Kim
Ho Sung Kim
Pyung Kil Kim
1. Lee JE, Jeon CH, Chang DK, Lee MS, Oh HY. Henoch–
Schonlein purpura associated with propylthiouracil overdose.
Nephrol Dial Transplant 2006; [Epub ahead of print]
2. Shin JI, Park JM, Lee JS, Kim DH, Jeong HJ. Development
of Graves’ disease during cyclosporin treatment for severe
Henoch–Schonlein nephritis. Nephrol Dial Transplant 2005; 20:
2014–2015
doi:10.1093/ndt/gfl287
Advance Access publication 30 May 2006
Cloudy dialysate due to lercanidipine
Sir,
Cloudy dialysate in a patient on continuous ambulatory
peritoneal dialysis (CAPD) results from a diverse group of
aetiologies. Most commonly, it reflects an increased number of
leucocytes secondary to bacterial peritonitis. However, an
occasional patient presents with leucocyte-negative, cloudy
dialysate. Dihydropyridine type calcium channel blockers
would cause turbid peritoneal dialysate [1]. In our study, we
investigated whether patients on CAPD having lercanidipine
(dihydropyridine type calcium channel blocker) treatment had
turbiditiy of peritoneal dialysate. We evaluated 23 patients
with end stage renal disease on CAPD, 14 female and nine
male, with the mean age of 45.3 17.6 years. The mean time
on CAPD was 15.9 11.6 months. The patients who enrolled
in this study were given lercanidipine 5mg/day. Peritoneal
dialysate was evaluated in terms of turbidity of dialysate on
the first day. Our diagnostic criteria for drug-induced turbidity
of dialysate as its development within the first day after the
treatment, absence of clinical symptoms of peritoneal inflam-
mation and the peritoneal dialysate containing normal
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